News
NURPF
8.22
NaN%
--
Neuren Expands Rett Syndrome Reach as DAYBUE STIX Goes Broadly U.S.-Available
TipRanks · 1d ago
Neuren Pharmaceuticals Reports Lapse of 50,000 Conditional Options
TipRanks · 03/26 07:49
Neuren Updates Market on Ongoing On-Market Share Buy-Back
TipRanks · 03/12 21:57
Neuren director Joseph Basile lifts stake with on-market share purchase
TipRanks · 03/05 23:33
Macquarie Sticks to Their Buy Rating for Neuren Pharmaceuticals Limited (NURPF)
TipRanks · 03/03 22:35
Neuren backs Acadia’s EMA appeal after CHMP rejection of Rett drug trofinetide
TipRanks · 03/02 23:34
Analysts Offer Insights on Healthcare Companies: Neuren Pharmaceuticals Limited (OtherNURPF), Mesoblast Limited (OtherMEOBF) and Ramsay Health Care (OtherRMSYF)
TipRanks · 03/01 23:10
Neuren Highlights Neurodevelopmental Focus and Development Risks in Investor Update
TipRanks · 02/27 01:37
Neuren Builds Cash and Pipeline as DAYBUE Royalties Climb in 2025
TipRanks · 02/27 01:08
Neuren profit falls on absence of one-offs as core royalties and R&D spend climb
TipRanks · 02/27 01:05
Neuren Rides DAYBUE Growth as 2025 Royalties Climb and 2026 Outlook Strengthens
TipRanks · 02/26 00:49
Neuren Pharmaceuticals Launches On-Market Share Buy-Back
TipRanks · 02/11 07:38
Neuren Schedules Investor Webinar as Rare Neurology Portfolio Advances
TipRanks · 02/11 06:18
Neuren launches on-market buy-back as board flags undervalued shares
TipRanks · 02/11 06:18
Neuren Pharmaceuticals Limited (NURPF) Gets a Buy from Jefferies
TipRanks · 02/06 12:17
Neuren Doses First Patient in Landmark Phase 3 Trial for Phelan-McDermid Syndrome
TipRanks · 02/05 23:19
Analysts Conflicted on These Healthcare Names: Neuren Pharmaceuticals Limited (OtherNURPF) and Pfizer (PFE)
TipRanks · 02/05 07:20
Analysts Offer Insights on Healthcare Companies: Neuren Pharmaceuticals Limited (OtherNURPF) and Bio-Techne (TECH)
TipRanks · 02/04 23:10
Neuren Set to Benefit as US Extends Rare Pediatric Disease Voucher Program to 2029
TipRanks · 02/04 21:28
Neuren Gains FDA Feedback Charting NNZ-2591 Path in HIE and Pitt Hopkins
TipRanks · 02/04 06:18
More
Webull provides a variety of real-time NURPF stock news. You can receive the latest news about Neuren Pharma through multiple platforms. This information may help you make smarter investment decisions.
About NURPF
Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing therapies for neurodevelopmental disorders. The Company is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Company’s product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product, NNZ-2591, is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The Company has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of NNZ-259 for Rett syndrome and Fragile X syndrome.